Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Signature Therapeutics, Inc.

Request full access

Signature Therapeutics is focused on creating novel medicines to improve upon the therapeutic utility of existing drugs

San Carlos, United StatesFounded 1967Biotech & Life Sciences

About Signature Therapeutics, Inc.

In 2004, a clinical-stage biopharmaceutical company called Signature Therapeutics was founded by Steven Shafer. The company, initially known as PharmacoFore, set out with a specific mission: to develop abuse-resistant prescription drugs. They focused on creating prodrugs, which are inactive medications that, once taken orally, become therapeutically active through the digestive process. This innovative approach aimed to tackle the growing problem of prescription drug misuse, particularly with opioids. The core of their work was the Bio-Activated Molecular Delivery (BIO-MD™) platform. This technology was designed to prevent abuse through non-oral methods like injection or inhalation. One of their key products was PF614, an abuse-deterrent version of Oxycodone. The company attracted investment, raising $10 million in a significant funding round in December 2011 from investors including Founders Fund and Westlake International Group. The company's journey culminated in a significant event. On December 31, 2015, Signature Therapeutics merged with Ensysce Biosciences. This merger created a more integrated drug delivery company, combining Signature's focus on abuse-deterrent small molecules with Ensysce's work on large molecule delivery. The combined entity continued under the Ensysce Biosciences name, relocating from Palo Alto to San Diego to advance the clinical trials for their pipeline of safer pain medications.

Source: Dealroom company data

At a glance

Status
Acquired
Open positions
None listed
Dealroom signal
23.3/100
Industry
Health, Security
Sub-industry
BioTechnology
Sector
Biotechnology
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Jan 2016 $0 — Ensysce Biosciences —
SERIES A✓Equity / VC Dec 2011 $10M $40M Founders Fund —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Signature Therapeutics, Inc. website traffic

Latest recorded traffic for Signature Therapeutics, Inc. is 0 monthly website visits.

Latest monthly visits0
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Signature Therapeutics, Inc. in the San Carlos ecosystem

Live from Dealroom

The Signature Therapeutics, Inc. office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Other known investors1 additional known investor

  • Ensysce Biosciences
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Carlos HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Signature Therapeutics, Inc. on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Signature Therapeutics, Inc.’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.